# The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19)

> **NCT04871828** · PHASE3 · UNKNOWN · sponsor: **King Abdullah International Medical Research Center** · enrollment: 66 (estimated)

## Conditions studied

- Moderate Covid19

## Interventions

- **DRUG:** Leukotriene Receptor Antagonist
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04871828
- **Lead sponsor:** King Abdullah International Medical Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-28
- **Primary completion:** 2021-09
- **Final completion:** 2021-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04871828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04871828, "The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04871828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*